Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Orbital myeloid sarcoma secondary to acute myeloblastic leukemia].
Ducloyer JB, Ducloyer M, Tessoulin B, Lebranchu P, Deltour JB. Ducloyer JB, et al. Among authors: tessoulin b. J Fr Ophtalmol. 2020 Jan;43(1):e15-e16. doi: 10.1016/j.jfo.2019.06.018. Epub 2019 Dec 5. J Fr Ophtalmol. 2020. PMID: 31813551 French. No abstract available.
A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia.
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Godon C, Mahé B, Dubruille V, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Tessoulin B, Le Gouill S, Moreau P, Béné MC, Chevallier P. Peterlin P, et al. Among authors: tessoulin b. Cancer Med. 2021 Jan;10(2):642-648. doi: 10.1002/cam4.3648. Epub 2020 Dec 25. Cancer Med. 2021. PMID: 33369136 Free PMC article.
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Boudreault JS, Perrin F, Lok A, Guillaume T, Garnier A, Peterlin P, Gallas P, Chevallier P, Moreau P, Le Gouill S. Tessoulin B, et al. Ann Hematol. 2017 Jun;96(6):943-950. doi: 10.1007/s00277-017-2981-2. Epub 2017 Apr 3. Ann Hematol. 2017. PMID: 28374163
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C. Trudel S, et al. Among authors: tessoulin b. Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14. Ann Hematol. 2019. PMID: 30874851
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C, Lok A, Tessoulin B, Gastinne T, Mahé B, Dubruille V, Blin N, Touzeau C, Moreau A, Bossard C, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Chevallier P, Moreau P, Leux C, Le Gouill S. Sortais C, et al. Among authors: tessoulin b. Ann Hematol. 2020 Jul;99(7):1595-1604. doi: 10.1007/s00277-020-04025-2. Epub 2020 May 16. Ann Hematol. 2020. PMID: 32417940
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C. Jullien M, et al. Among authors: tessoulin b. Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14. Ann Hematol. 2019. PMID: 30874850
77 results